Article in American journal of physiology. Cell physiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
10 authors.
Brandon N VanderVeenDepartment of Pathology, Microbiology, and Immunology, University of South Carolina School of Medicine, Columbia, South Carolina, United States.ORCID 0000-0002-4535-0544
Thomas D CardaciDepartment of Pathology, Microbiology, and Immunology, University of South Carolina School of Medicine, Columbia, South Carolina, United States.ORCID 0000-0002-4339-819X
Brooke M BullardDepartment of Pathology, Microbiology, and Immunology, University of South Carolina School of Medicine, Columbia, South Carolina, United States.ORCID 0000-0003-0923-9950
Christian A UngerDepartment of Pathology, Microbiology, and Immunology, University of South Carolina School of Medicine, Columbia, South Carolina, United States.
Jeffrey C FreemanDepartment of Pathology, Microbiology, and Immunology, University of South Carolina School of Medicine, Columbia, South Carolina, United States.ORCID 0009-0008-3244-6863
Reilly T EnosDepartment of Pathology, Microbiology, and Immunology, University of South Carolina School of Medicine, Columbia, South Carolina, United States.ORCID 0000-0001-5571-4586
Michael ShtutmanDepartment of Drug Discovery & Biomedical Sciences, College of Pharmacy, University of South Carolina, Columbia, South Carolina, United States.ORCID 0000-0002-2458-3226
Michael D WyattDepartment of Drug Discovery & Biomedical Sciences, College of Pharmacy, University of South Carolina, Columbia, South Carolina, United States.
Daping FanDepartment of Cell Biology and Anatomy, University of South Carolina School of Medicine, Columbia, South Carolina, United States.
E Angela MurphyDepartment of Pathology, Microbiology, and Immunology, University of South Carolina School of Medicine, Columbia, South Carolina, United States.ORCID 0000-0002-4803-5822
Funding
A Transdisciplinary Approach to Investigating Metabolic Dysregulation in Obese Parent and Child Dyads and Risk of Colorectal Cancer - admin supplementU01CA272977 · NCI · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI JAMES R HEBERT, Lorne J Hofseth · 2022 to 2026
$4.7M
B-cell-intrinsic MHCII Signaling is a Diversifying Force of Selection on IgA Repertoires and the Gut MicrobiotaR01AI155887 · NIAID · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI KUBINAK, JASON L · 2021 to 2025
$2.1M
BD FACSymphony A5 Cell AnalyzerS10OD032271 · OD · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI KUBINAK, JASON L, PRICE, ROBERT L · 2022 to 2022
$513k
Impact of Obesity on Chemotherapy-Induced Cytotoxicity: Immune Cells and Skeletal MuscleR00CA276891 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI Brandon VanderVeen · 2025 to 2026
$498k
Impact of Obesity on Chemotherapy-Induced Cytotoxicity: Immune Cells and Skeletal MuscleK99CA276891 · NCI · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI VANDERVEEN, BRANDON · 2023 to 2024
$260k
Impact of obesity on chemotherapy-induced muscle mitochondrial dysfunctionF31CA278490 · NCI · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI CARDACI, THOMAS · 2023 to 2024
$50k
HHS | NIH | National Cancer Institute (NCI) F31CA278490HHS | NIH | National Cancer Institute (NCI) K99CA276891HHS | NIH | National Cancer Institute (NCI) S10OD032271HHS | NIH | National Cancer Institute (NCI) U01CA272977HHS | NIH | National Institute of General Medical Sciences (NIGMS) S10OD032271NCI NIH HHS F31 CA278490NCI NIH HHS K99 CA276891NCI NIH HHS R00 CA276891NCI NIH HHS U01 CA272977NIAID NIH HHS R01 AI155887NIH HHS S10 OD032271
6 · The paper itself
Abstract
Obesity increases the risk for developing several cancers, including colorectal cancer (CRC), and is associated with liver perturbations, which likely impacts treatment tolerance. 5 fluorouracil (5FU) remains a first line treatment for CRC, but efficacy is hampered by interpatient variable responsiveness and off-target toxicities. The current study examined the impact of diet-induced obesity (DIO) on 5FU cytopenia and efficacy using two established CRC models: MC38 (C57BL/6) and C26 (CD2F1). DIO increased tumor size in both MC38 and C26. DIO reduced liver dihydropyrimidine dehydrogenase (
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
The impact of diet-induced obesity on 5 fluorouracil-induced tumor and liver immune cell cytotoxicity. · full record | Socratic